Which cytotoxic payload: chemotherapeutic (ADC) or radionuclide (ARC) ? Curr Cancer Therapy Rev, vol.12, p.54, 2016. ,
Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibody, Cancer Res, vol.50, pp.1039-1081, 1990. ,
Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer, J Nucl Med, vol.37, pp.1853-1862, 1996. ,
Radioimmunotherapy of micrometastases: a continuing evolution, J Nucl Med, vol.33, pp.2180-2183, 1992. ,
Rationales, evidence, and design considerations for fractionated radioimmunotherapy, Cancer, vol.94, pp.1332-1380, 2002. ,
Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy, J Natl Cancer Inst, vol.82, pp.763-71, 1990. ,
, , vol.90
, Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria, J Clin Oncol, vol.32, pp.212-220, 2014.
Yttriumibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial, J Clin Oncol, vol.90, pp.308-321, 2013. ,
Fractionated dose radiolabeled antiprostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) with or without docetaxel for metastatic castration-resistant prostate cancer (mCRPC), ASCO Meeting Abstr, vol.33, p.194, 2015. ,
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer, Clin Cancer Res, vol.19, pp.5182-91, 2013. ,
Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil), Cancer Res, vol.57, pp.2181-2187, 1997. ,
A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies, Clin Cancer Res, vol.6, pp.3855-63, 2000. ,
A phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer, Clin Cancer Res, vol.9, pp.5842-52, 2003. ,
Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial, Clin Cancer Res, vol.17, pp.4091-100, 2011. ,
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: a phase 1 trial, Cancer, vol.118, pp.5497-506, 2012. ,
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer, J Clin Oncol, vol.23, pp.4591-601, 2005. ,
Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody 177lu-J591 in patients with metastatic, castrationresistant prostate cancer (mCRPC), ASCO Meeting Abstr, vol.32, p.5064, 2014. ,
Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPAindium bispecific antibody, J Nucl Med, vol.39, pp.1172-1180, 1998. ,
Tumor immunotargeting using innovative radionuclides, Int J Mol Sci, vol.16, pp.3932-54, 2015. ,
Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement, J Nucl Med, vol.53, pp.1185-92, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00932253
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting, Proc Natl Acad Sci, vol.103, pp.6841-6847, 2006. ,
A universal pretargeting system for cancer detection and therapy using bispecific antibody, Cancer Res, vol.63, pp.354-63, 2003. ,
Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice, J Nucl Med, vol.51, pp.1780-1787, 2010. ,
Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer, Eur J Nucl Med Mol Imaging, vol.41, pp.1593-602, 2014. ,
Pharmacokinetics and dosimetry studies for optimization of Pretargeted Radioimmunotherapy in CEA-expressing advanced lung Cancer patients, Front Med (Lausanne), vol.2, p.84, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01258870
Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors, J Cancer Res Ther, vol.5, issue.1, pp.36-40, 2009. ,
Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted ?-particle therapy, Cancer Biother Radiopharm, vol.28, pp.1-20, 2013. ,
Targeted alpha particle immunotherapy for myeloid leukemia, Blood, vol.100, pp.1233-1242, 2002. ,
Targeted alpha-particle immunotherapy for acute myeloid leukemia, Am Soc Clin Oncol Educ Book, pp.126-157, 2014. ,
Dose escalation and dosimetry of first-in-human ? radioimmunotherapy with 212Pb-TCMC-trastuzumab, J Nucl Med, vol.55, pp.1636-1678, 2014. ,
Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model, Blood, vol.121, pp.3759-67, 2013. ,
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6, J Nucl Med, vol.49, pp.30-38, 2008. ,
Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2 -a phase I study, J Nucl Med, vol.50, pp.1153-60, 2009. ,
Radioimmunoconjugates for the treatment of cancer, Semin Oncol, vol.41, pp.613-635, 2014. ,
Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors, EJNMMI Res, vol.1, issue.20, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00626326
Immuno-PET imaging and radioimmunotherapy of 64Cu-/177Lu-labeled anti-EGFR antibody in esophageal squamous cell carcinoma model, J Nucl Med, vol.57, p.1105, 2016. ,
Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET, Eur J Nucl Med Mol Imaging, vol.39, pp.512-532, 2012. ,
Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography, Eur J Nucl Med Mol Imaging, vol.33, pp.1337-1382, 2006. ,